Evidence map›Paper›PMID 41094042›Full record

ArticleScientific reports2025

Animal-free alternatives for Matrigel in human iPSC-derived blood vessel organoid culture.

Rachel Giles, Elana M Meijer, Renée G C Maas, Christian G M van Dijk, Marianne C Verhaar, Caroline Cheng

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rachel Giles *Department of Nephrology and Hypertension, University Medical Centre Utrecht, PO Box 85500, Utrecht, 3508 GA, The Netherlands.
Elana M Meijer *Department of Nephrology and Hypertension, University Medical Centre Utrecht, PO Box 85500, Utrecht, 3508 GA, The Netherlands.
Renée G C MaasDepartment of Cardiology, Regenerative Medicine Centre Utrecht, University Medical Centre Utrecht, Utrecht, The Netherlands.
Christian G M van DijkDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, PO Box 85500, Utrecht, 3508 GA, The Netherlands.
Marianne C VerhaarDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, PO Box 85500, Utrecht, 3508 GA, The Netherlands.
Caroline ChengDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, PO Box 85500, Utrecht, 3508 GA, The Netherlands. K.L.Cheng-2@umcutrecht.nl.

Funding

Dutch Cardiovascular Alliance 2020B008 ReconnextRegMed XB cardiovascular moonshot consortium and the NWO vidi grant 91714302
6 · The paper itself

Abstract

The use of blood vessel organoids (BVOs), or vascular organoids derived from human induced pluripotent stem cells (hiPSC), provides a valuable tool for research on vascular regeneration. Vascular organoid culture relies on the use of Matrigel, a murine sarcoma-derived matrix, which limits its translational potential and reproducibility. This study evaluated the potential alternatives to Matrigel for both 2D hiPSC and 3D vascular organoid culture to enhance the clinical applicability of hiPSC-derived vascular organoids. Vitronectin is a suitable replacement for Matrigel in hiPSC culture and expansion, maintaining pluripotency and facilitating subsequent differentiation into vascular organoids. Additionally, we demonstrated that fibrin-based hydrogels effectively support vascular organoid differentiation, promoting vascular network formation and endothelial cell sprouting comparable to Matrigel-based cultures. Through gene expression analysis, surface area quantification, and immunohistochemistry, we validated the efficacy of Vitronectin and fibrin in supporting hiPSC-derived vascular organoid differentiation. This Matrigel-free protocol not only enhances reproducibility but is a step forward in xeno-free culture conditions, offering a versatile platform for disease modelling, vascular tissue engineering, and patient-specific therapeutic screening.

Indexed as

Blood VesselsCell Culture TechniquesCollagenInduced Pluripotent Stem CellsLamininOrganoidsProteoglycansCell DifferentiationDrug CombinationsEndothelial CellsFibrinHumansHydrogelsTissue EngineeringVitronectinCollagenDrug CombinationsFibrinHydrogelsLamininmatrigelProteoglycansVitronectinAnimal-free alternativesMatrigel replacementVascular organoidsVascular regeneration

Identifiers

PMID41094042
PMCPMC12528733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.